Reappraisal of the clinical effect of mepolizumab

Affiliations

¹ Scottish Centre for Respiratory Research, Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, UK. Electronic address: b.j.lipworth@dundee.ac.uk.
² Scottish Centre for Respiratory Research, Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, UK.

Comment

Brian J Lipworth et al. Lancet Respir Med. 2017 Jun.

. 2017 Jun;5(6):e20.

doi: 10.1016/S2213-2600(17)30183-2. Epub 2017 May 26.

¹ Scottish Centre for Respiratory Research, Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, UK. Electronic address: b.j.lipworth@dundee.ac.uk.
² Scottish Centre for Respiratory Research, Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, UK.

No abstract available

Comment in

Reappraisal of the clinical effect of mepolizumab - Authors' reply.
Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A. Chupp GL, et al. Lancet Respir Med. 2017 Jun;5(6):e21. doi: 10.1016/S2213-2600(17)30184-4. Epub 2017 May 26. Lancet Respir Med. 2017. PMID: 28664853 No abstract available.

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A. Chupp GL, et al. Lancet Respir Med. 2017 May;5(5):390-400. doi: 10.1016/S2213-2600(17)30125-X. Epub 2017 Apr 5. Lancet Respir Med. 2017. PMID: 28395936 Clinical Trial.